{"DataElement":{"publicId":"2676555","version":"1","preferredName":"Breast Carcinoma Diagnosis Time Stage","preferredDefinition":"A description of the stage of the breast carcinoma at diagnosis.","longName":"BRST_CRCN_DX_TME_STG","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2676553","version":"1","preferredName":"Breast Carcinoma Diagnosis Time","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._The continuum of experience in which events pass from the future through the present to the past.","longName":"BRST_CRCN_DX_TME","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2475941","version":"1","preferredName":"Breast Carcinoma","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002","longName":"C4872","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11C95199-159B-5C1E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2688307","version":"1","preferredName":"Diagnosis Time","preferredDefinition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.:the continuum of experience in which events pass from the future through the present to the past.","longName":"C15220:C25207","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C1379EC-B440-1F96-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-09","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-09","modifiedBy":"ONEDATA","dateModified":"2007-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39512787-07DC-12A5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".Updated def with 2 words spelling corrected. No version needed. AK 9/19/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2676540","version":"1","preferredName":"Breast Carcinoma Stage","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"BRST_CRCN_STG","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"Stage 0 Breast Cancer","ValueMeaning":{"publicId":"2577125","version":"1","preferredName":"Stage 0 Breast Cancer","longName":"2577125","preferredDefinition":"Stage 0 Breast Cancer","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Breast Cancer AJCC v6 and v7","conceptCode":"C3641","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"SBREXT","dateModified":"2005-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39510EA0-2861-0DF1-E044-0003BA3F9857","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"ALEYR","dateModified":"2007-09-04","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Breast Cancer","ValueMeaning":{"publicId":"2676546","version":"1","preferredName":"Stage I Breast Cancer","longName":"2676546","preferredDefinition":"Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Breast Cancer AJCC v6","conceptCode":"C7767","definition":"Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39510EA0-2870-0DF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39510EA0-2889-0DF1-E044-0003BA3F9857","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"ALEYR","dateModified":"2007-09-04","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Breast Cancer","ValueMeaning":{"publicId":"2676548","version":"1","preferredName":"Stage II Breast Cancer","longName":"2676548","preferredDefinition":"Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, MO); (T3,NO,MO).  T0: No evidence of primary tumor.  T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th Ed.) - 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Breast Cancer AJCC v6 and v7","conceptCode":"C7768","definition":"Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39510EA0-2898-0DF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39510EA0-28B1-0DF1-E044-0003BA3F9857","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"ALEYR","dateModified":"2007-09-04","deletedIndicator":"No"},{"value":"III","valueDescription":"Stage III Breast Cancer","ValueMeaning":{"publicId":"2676550","version":"1","preferredName":"Stage III Breast Cancer","longName":"2676550","preferredDefinition":"Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.) - 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Breast Cancer AJCC v6","conceptCode":"C7769","definition":"Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39510EA0-28C0-0DF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39510EA0-28D9-0DF1-E044-0003BA3F9857","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"ALEYR","dateModified":"2007-09-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2677048","version":"1","preferredName":"Breast Carcinoma Stage","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C4872:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3961E549-8B15-4D1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-05","modifiedBy":"ONEDATA","dateModified":"2007-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"394F95CB-C8B1-6630-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"KUMMEROA","dateModified":"2012-09-19","changeDescription":".Updated def for \"breast\". No version needed. AK 9/19/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2716207","version":"1","longName":"ASCO (American Society of Clinical Oncology)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812713","version":"1","longName":"Breast Cancer Adjuvant Treatment","context":"NCIP"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_brst_ca_stat_diag","type":"NMDP_FN","context":"NHLBI"},{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"PerformedClinicalInterpretation:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"What was the stage of the bre","type":"Preferred Question Text","description":"What was the stage of the breast cancer at diagnosis?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2676555","type":"BRIDG Mapping Path","description":"PerformedDiagnosis > AssessedResultRelationship > PerformedObservation (1) > PerformedClinicalInterpretation.value WHERE PerformedDiagnosis.value = \"breast cancer\" AND AssessedResultRelationship.typeCode = \"staging\" AND PerformedDiagnosis > PerformedObservation.dateRange (2) = PerformedObservation.dateRange (1)","url":null,"context":"NHLBI"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Breast cancer stage?","url":null,"context":"Alliance"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39513484-8F87-15D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"KUMMEROA","dateModified":"2021-06-07","changeDescription":".2021-6-7 ak System generated def displayed as alt def. Updated def for \"breast\". No version needed. AK 9/19/12 .1/8/14mn-added Bridg info.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}